{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T22:17:02Z","timestamp":1782425822960,"version":"3.54.5"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Recurrent respiratory papillomatosis (RRP) is the most common as well as the costliest benign airway neoplasm in the United States [Ivancic <jats:italic toggle=\"yes\">et al.<\/jats:italic> (2018). Laryngoscope Investig Otolaryngol 3:22; Derkay (1995). Arch Otolaryngol Head Neck Surg 121:1386]. In addition, it is potentially deadly, with risk of airway obstruction as well as a 3\u20137% risk of malignant conversion [Schraff <jats:italic toggle=\"yes\">et al.<\/jats:italic> (2004). Arch Otolaryngol Head Neck Surg 130:1039]. This review highlights exciting advancements over the past 1\u20132 years in scientific understanding of the pathophysiology, epidemiology, natural history, prevention, and treatment of this difficult disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent studies have yielded the following findings: The primary quality of life reduction that patients perceive is voice-related; the membranous vocal folds are the most frequently involved anatomic subsite in adult-onset RRP; there may be a correlation between laryngopharyngeal reflux, herpes simplex virus type 2, and adult-onset RRP; there has been a decline in RRP incidence in Australia following the implementation of a national vaccination program; addition of educational audiovisual aids assists in vaccine acceptance rates; preventive vaccination can be used as treatment for pediatric as well as adult RRP patients with demonstrable effects on antibody titers and reoperation rates; calreticulin-linked DNA vaccines show promise in reducing the growth rate of human papilloma virus (HPV)11 E6\/E7-expressing tumors in mice; injection of bevacizumab is associated with no adverse tissue affects; systemic bevacizumab is effective as a treatment for severe uncontrolled disease; pegylated interferon treatment is effective in select severe pediatric RRP disease; and finally, increased rates of programed death 1 T-lymphocyte infiltration and programed death-ligand 1 expression are seen on both papilloma and infiltrating immune cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>RRP is declining in incidence but remains a challenging disease to treat with great costs to patients, families, and the healthcare system. As the disease continues to be better understood, new frontiers are opening in treatment, particularly for severe or poorly controlled disease. Until the disease can be eradicated, it remains a vital area of research to help prevent new cases and treat afflicted patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/moo.0000000000000490","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T12:25:27Z","timestamp":1539087927000},"page":"421-425","source":"Crossref","is-referenced-by-count":35,"title":["Recurrent respiratory papillomatosis: update 2018"],"prefix":"10.1097","volume":"26","author":[{"given":"Craig S.","family":"Derkay","sequence":"first","affiliation":[{"name":"Department of Otolaryngology \u2013 Head and Neck Surgery"},{"name":"Pediatric Otolaryngology, Eastern Virginia Medical School"},{"name":"Children's Hospital of the King's Daughters"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Bluher","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head and Neck Surgery"},{"name":"Eastern Virginia Medical School, Sentara Norfolk General Hospital, Norfolk, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/archotol.126.8.935","article-title":"The cost of juvenile-onset recurrent respiratory papillomatosis","volume":"126","author":"Bishai","year":"2000","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/lary.26413","article-title":"Quality of life of patients with recurrent respiratory papillomatosis","volume":"127","author":"San Giorgi","year":"2017","journal-title":"Laryngoscope"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/archotol.1995.01890120044008","article-title":"Task force on recurrent respiratory papillomas. A preliminary report","volume":"121","author":"Derkay","year":"1995","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/MOO.0b013e328316930e","article-title":"Recurrent respiratory papillomatosis: update 2008","volume":"16","author":"Gallagher","year":"2008","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/lary.26742","article-title":"Laryngeal distribution of recurrent respiratory papillomatosis in a previously untreated cohort","volume":"128","author":"Benedict","year":"2018","journal-title":"Laryngoscope"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/coa.12779","article-title":"Laryngopharyngeal reflux and herpes simplex virus type 2 are possible risk factors for adult-onset recurrent respiratory papillomatosis (prospective case\u2013control study)","volume":"42","author":"Form\u00e1nek","year":"2017","journal-title":"Clin Otolaryngol"},{"key":"R7-20230917","first-page":"208","article-title":"A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a National HPV Vaccination Program","volume":"217","author":"Novakovic","year":"2018","journal-title":"J Infect Dis"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"874","DOI":"10.15585\/mmwr.mm6633a2","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 Years \u2013 United States, 2016","volume":"66","author":"Walker","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"R9-20230917","article-title":"Multimodal counseling interventions: effect on human papilloma virus vaccination acceptance","volume":"5","author":"Nwanodi","year":"2017","journal-title":"Healthcare (Basel)"},{"issue":"(2S)","key":"R10-20230917","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.acap.2017.09.014","article-title":"Ten years of human papillomavirus vaccination in the United States","volume":"18","author":"Markowitz","year":"2018","journal-title":"Acad Pediatr"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijporl.2016.12.035","article-title":"Therapeutic use of the HPV vaccine in recurrent respiratory papillomatosis: a case report","volume":"93","author":"Sullivan","year":"2017","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jvoice.2016.01.008","article-title":"Gardasil vaccination for recurrent laryngeal papillomatosis in adult men: first report: changes in HPV antibody titer","volume":"31","author":"Makiyama","year":"2017","journal-title":"J Voice"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/lio2.80","article-title":"Recurrent respiratory papillomatosis (RRP)-time for a reckoning?","volume":"2","author":"Kin Cho Goon","year":"2017","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamaoto.2016.4736","article-title":"Adjuvant human papillomavirus vaccination for secondary prevention: a systematic review","volume":"143","author":"Dion","year":"2017","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1002\/lary.26737","article-title":"Immunologic responses to a novel DNA vaccine targeting human papillomavirus-11 E6E7","volume":"127","author":"Ahn","year":"2017","journal-title":"Laryngoscope"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archotol.130.9.1039","article-title":"American Society of Pediatric Otolaryngology members\u2019 experience with recurrent respiratory papillomatosis and the use of adjuvant therapy","volume":"130","author":"Schraff","year":"2004","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R17-20230917","doi-asserted-by":"crossref","DOI":"10.1590\/1516-3180.2017.0031240317","article-title":"Pegylated interferon for treating severe recurrent respiratory papillomatosis in a child: case report","author":"Maunsell","year":"2017","journal-title":"Sao Paulo Med J"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/lary.26185","article-title":"Effect of high-dose vocal fold injection of cidofovir and bevacizumab in a porcine model","volume":"127","author":"Ahmed","year":"2017","journal-title":"Laryngoscope"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/lary.26450","article-title":"Bevacizumab chemotherapy for management of pulmonary and laryngotracheal papillomatosis in a child","volume":"127","author":"Zur","year":"2017","journal-title":"Laryngoscope"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/lary.26662","article-title":"Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey","volume":"127","author":"Best","year":"2017","journal-title":"Laryngoscope"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"842","DOI":"10.12659\/AJCR.904416","article-title":"Systemic bevacizumab for recurrent respiratory papillomatosis: a single center experience of two cases","volume":"18","author":"Bedoya","year":"2017","journal-title":"Am J Case Rep"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1002\/lary.26847","article-title":"The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis","volume":"128","author":"Ahn","year":"2018","journal-title":"Laryngoscope"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/lio2.132","article-title":"Current and future management of recurrent respiratory papillomatosis","volume":"3","author":"Ivancic","year":"2018","journal-title":"Laryngoscope Investig Otolaryngol"}],"container-title":["Current Opinion in Otolaryngology &amp; Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00020840-201812000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T08:27:12Z","timestamp":1694939232000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00020840-201812000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/moo.0000000000000490","relation":{},"ISSN":["1068-9508","1531-6998"],"issn-type":[{"value":"1068-9508","type":"print"},{"value":"1531-6998","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}